Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.79 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | ITK | Q08881 | 2/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | TEC | P42680 | 1/20 | 0.54 |
| ▸ | TXK | P42681 | 1/20 | 0.54 |
| ▸ | BMX | P51813 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | CD69 | Q07108 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656265 | 0.91 | SYK (0.80) | SYKAURKABTK | |
| SCHEMBL656511 | 0.89 | SYK (1.00) | SYKEGFRITKAURKA | |
| SCHEMBL655884 | 0.84 | SYK (0.85) | SYKEGFRITKAURKABTK | |
| SCHEMBL15814263 | 0.84 | SYK (0.74) | SYKEGFRITKAURKABTK | |
| SCHEMBL653838 | 0.84 | SYK (1.00) | SYKEGFRITKAURKA | |
| SCHEMBL654783 | 0.84 | SYK (0.78) | SYKEGFRITKAURKABTK | |
| SCHEMBL656766 | 0.84 | SYK (1.00) | SYKEGFRITKAURKA | |
| SCHEMBL655466 | 0.83 | SYK (1.00) | SYKITKAURKABTKJAK2 | |
| SCHEMBL657193 | 0.83 | SYK (0.86) | SYKEGFRITKAURKA | |
| SCHEMBL21110441 | 0.82 | SYK (0.80) | SYKEGFRITKBTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308105-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | Trained Therapeutix Discovery, Inc. (US) | 2024-01-24 | — | — | EP | claimed |
| EP-4232060-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | The Regents Of The University Of Michigan (US) | 2023-08-30 | — | — | EP | claimed |
| WO-2022198101-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | TRAINED THERAPEUTIX DISCOVERY, INC. (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022087058-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-28 | — | — | WO | claimed |
| EP-2130541-A2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | claimed |
| EP-1425112-A4 | NANOGELS AND THEIR PRODUCTION USING LIPOSOMES AS REACTORS | UNIV POLYTECHNIC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1511580-A4 | LIPOBEADS AND THEIR PRODUCTION | UNIV POLYTECHNIC (US) | 2005-06-08 | — | — | EP | claimed |
| EP-1511580-A2 | LIPOBEADS AND THEIR PRODUCTION | POLYTECHNIC UNIVERSITY (US) | 2005-03-09 | — | — | EP | claimed |
| EP-1425112-A1 | NANOGELS AND THEIR PRODUCTION USING LIPOSOMES AS REACTORS | POLYTECHNIC UNIVERSITY (US) | 2004-06-09 | — | — | EP | claimed |
| WO-2003015701-A9 | LIPOBEADS AND THEIR PRODUCTION | UNIV POLYTECHNIC (US) | 2003-04-24 | — | — | WO | claimed |
| WO-2003015936-A1 | NANOGELS AND THEIR PRODUCTION USING LIPOSOMES AS REACTORS | POLYTECHNIC UNIVERSITY (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2003015701-A2 | LIPOBEADS AND THEIR PRODUCTION | POLYTECHNIC UNIVERSITY (US) | 2003-02-27 | — | — | WO | claimed |
| EP-4308105-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | Trained Therapeutix Discovery, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4232060-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | The Regents Of The University Of Michigan (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022198101-A1 | COMPOUNDS FOR REGULATING TRAINED IMMUNITY, AND THEIR METHODS OF USE | TRAINED THERAPEUTIX DISCOVERY, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-1071401-A4 | LIPOSOMAL BUPIVACAINE COMPOSITIONS AND METHODS OF PREPARATION | YISSUM RES DEV CO (IL) | 2002-05-15 | — | — | EP | disclosed |
| EP-1071401-A1 | LIPOSOMAL BUPIVACAINE COMPOSITIONS AND METHODS OF PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999049849-A1 | LIPOSOMAL BUPIVACAINE COMPOSITIONS AND METHODS OF PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | FCER2, FCGR1A, FCGR2A | SYK 4/4885EGFR 276/4885ITK 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.